

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GIANT BIOGENE HOLDING CO., LTD

巨子生物控股有限公司

(An exempted company incorporated in the Cayman Islands with limited liability)

(Stock code: 2367)

RESIGNATION OF NON-EXECUTIVE DIRECTOR APPOINTMENT OF EXECUTIVE DIRECTORS AND SENIOR MANAGEMENT

Resignation of Non-executive Director

The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of Giant Biogene Holding Co., Ltd (the “**Company**”) hereby announces that Mr. Chen Jinhao (“**Mr. Chen**”) has tendered his resignation as a non-executive Director with effect from 3 October 2023 due to work arrangements.

Mr. Chen has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. Chen for his valuable contributions to the Company during his tenure of office.

Appointment of Executive Directors and Senior Management

The Board is pleased to announce that Ms. Zhang Huijuan (“**Ms. Zhang**”) was appointed as an executive Director, and Ms. Yan Yubo (“**Ms. Yan**”) was appointed as an executive Director and the chief product officer of the Company with effect from 3 October 2023.

The biographical details of Ms. Zhang and Ms. Yan are set out respectively as follows:

Ms. Zhang Huijuan, aged 37, is currently the chief financial officer of the Company. Ms. Zhang has approximately 15 years of experience in accounting and financial management. Prior to joining the Group, she was a senior auditor in Tianjin Branch of Deloitte Touche Tohmatsu Certified Public Accountants LLP (德勤華永會計師事務所(特殊普通合夥)) from July 2008 to December 2010. She then joined Xi’an Branch of PricewaterhouseCoopers Zhong Tian LLP (普華永道中天會計師事務所(特殊普通合夥)) as an audit manager from January

2011 to September 2018. She served as the director of financial department at Easy Click Worldwide Network Technology Co., Ltd. (易點天下網絡科技股份有限公司) from April 2019 to January 2022. Ms. Zhang obtained the certificate of certified public accountant from the PRC Ministry of Finance in December 2017, the certificate of certified internal auditor from the Institute of Internal Auditors in March 2015, and the certificate of intermediate accountant from the PRC Ministry of Human Resources and Social Security and the PRC Ministry of Finance in October 2013. Ms. Zhang obtained a bachelor's degree in Japanese (international business) from Tianjin Foreign Studies University (天津外國語大學) in July 2008. According to the RSU Scheme adopted by the Company on 8 December 2021, Ms. Zhang is entitled to RSUs equivalent to 800,000 shares (subject to vesting conditions), which are held under a trust pursuant to the RSU Scheme.

Ms. Yan Yubo, aged 28, is currently a joint company secretary and the Board secretary of the Company. Ms. Yan joined Xi'an Giant Biogene Technology Co., Ltd. in October 2018 as the board secretary and has been responsible for the affairs related to the Group's financing, investor relationship management and corporate governance since then. Ms. Yan obtained the certificate of Financial Risk Manager (FRM) from the Global Association of Risk Professionals in March 2021, the securities qualification certificate from the Securities Association of China in April 2021, the certificate of board secretary from Shanghai Stock Exchange in September 2020, the certificate of board secretary from Shenzhen Stock Exchange in July 2020, and the qualification certificate of fund practitioner from the Asset Management Association of China in November 2019. Ms. Yan obtained a bachelor's degree from the University of Toronto in Canada in June 2017, double majoring in financial economics and statistics. Ms. Yan obtained a master's degree in applied economics from the University of California, Los Angeles in the United States in June 2018. Ms. Yan is (i) the daughter of Mr. Yan Jianya, the chairman of the Board, executive Director and chief executive officer, and Dr. Fan Daidi, the controlling Shareholder; and (ii) a niece of Ms. Yan Yajuan, a senior vice president of the Company.

Ms. Zhang and Ms. Yan have entered into service contracts with the Company for a term of three years commencing from 3 October 2023, respectively, and are subject to (i) retirement and re-election at the first annual general meeting of the Company after their appointments; and (ii) retirement by rotation and re-election at least once every three years in accordance with the articles of association of the Company and the Corporate Governance Code as set out in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). During the tenures of Ms. Zhang and Ms. Yan as executive Directors, they are entitled to receive remunerations based on their management positions in the Company. Their actual annual remunerations will be determined based on the factors such as market conditions, the Company's performance and the results of their performance appraisals conducted by the Board. They will not receive any additional Director's fees for holding the office of executive Directors.

Save as disclosed above, as at the date of this announcement, Ms. Zhang and Ms. Yan have confirmed respectively that they (i) do not hold any other positions in the Company or any of its subsidiaries; (ii) did not hold any directorship in any other public companies, the securities of which are listed on any securities markets in Hong Kong or overseas in the past three years; or (iii) do not hold any other major appointments or professional qualifications.

Save as disclosed above, as at the date of this announcement, Ms. Zhang and Ms. Yan have respectively confirmed that they do not have any relationship with any Directors, senior management or substantial or controlling Shareholders of the Company, or hold any interests in the shares of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, there is no other information required to be disclosed pursuant to the Rule 13.51(2)(h) to (v) of the Listing Rules, nor any other matters relating to Ms. Zhang and Ms. Yan's appointments that need to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to extend its warm welcome to Ms. Zhang and Ms. Yan on their appointments.

By Order of the Board
Giant Biogene Holding Co., Ltd
YAN Jianya
Chairman of the Board

Xi'an, the PRC, 3 October 2023

As at the date of this announcement, the Board comprises Mr. Yan Jianya, Ms. Ye Juan, Ms. Fang Juan, Ms. Zhang Huijuan and Ms. Yan Yubo as executive Directors, and Mr. Huang Jin, Mr. Shan Wenhua and Ms. Wong Sze Wing as independent non-executive Directors.